Lani
05-18-2011, 11:12 PM
I have previously hypothesized about this as well and it may be the reason her2+ er+ luminal B behavior was not that different from that of her2- luminal B tumors (speculation on my part, but fits the findings)
Luminal B breast cancer and prognostic value of HER2 overexpression: Retrospective analysis of a single-institution series.
Sub-category:
HER2+
Category:
Breast Cancer - HER2/ER
Meeting:
2011 ASCO Annual Meeting
Abstract No:
e11120
Citation:
J Clin Oncol 29: 2011 (suppl; abstr e11120)
Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2011 Annual Meeting but not presented at the Meeting, can be found online only.
The publication-only abstracts are not included in the print or USB versions of the ASCO Annual Meeting Proceedings Part I, but they are citable to the Journal of Clinical Oncology as a supplement (see citation on left).
Author(s): C. A. Castaneda, E. Andres, N. Valdivieso, M. Dorta, L. Manso, I. Ghanem, H. Cortes-Funes, E. M. Ciruelos Gil; Hospital Universitario 12 de Octubre, Madrid, Spain; Unidad de Investigación, Madrid, Spain; Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, Spain
Abstract Disclosures
Abstract:
Background: Luminal B is a heterogeneous estrogen-receptor positive breast cancer subtype, with a higher proliferation rate and a poorer prognosis than luminal A. Overexpression of HER2 oncogene identifies tumors with a different clinical behavior. This study evaluates the prognostic role of HER2 expression in luminal B tumors. Methods: We retrospectively analyzed the clinicopathologic characteristics of 2005 early breast cancer pts (I-IIIB clinical stages) diagnosed between 1997 and 2007 at our institution. 47% of pts fulfill luminal B-subtype criteria: ki67≥14%, PR<10% stained cells or HER2(+) in addition to ER≥10% stained cells. HER2 was defined as positive if Herceptest 3+or gene amplification confirmed by FISH. Results: Among 772 luminal B patients who received curative surgery for invasive breast cancer from January 1997 to June 2007, 670 patients were included in this analysis, and 212 (27,4%) cases were HER2(+). Median age was 54.4 years (range: 27-87 years). Histologic subtype was as follows: ductal 562 pts (83.9 %); lobular 82 pts (12.2%) Histologic grade: I: 15.1 %, II: 44.8 % , and III: 39 %. Tumor characteristics according to HER2 status were similar, as described in table. With a median follow-up of 82 months, overall relapse rate was 23%. Median DFS or OS were not reached. At the current analysis, no differences were observed in DFS (p 0.64) or OS (p 0.53) in Kaplan-Meier estimates between HER2 positive and negative groups. Conclusions: Luminal B subtype include populations with different behaviour and prognosis. In our series patients with HER2 (+) tumors have a similar prognosis as HER2(-) subgroup for luminal B classified patients.
Tumor or patient characteristic
HER2-negative subgroup (% pts) HER2-positive subgroup (% pts)
Median age 54.7 y 53.4 y
Median Ki67 value 20 20
Tumor size
T1
T2
T3
T4 46.2
40.3
8.6
4.2 44.9
44.9
4.8
7.2
Node status
N0
N1
N2
N3 52.0
28.8
11.8
7.2 57.5
21.7
14.6
6.13
Histologic type
Ductal
Lobular 80
15 92
5.6
Adjuvant chemotherapy
None
No taxanes nor anthracyclines
Anthracyclines without taxanes
Anthracyclines and taxanes 19.7
15.1
24.3
23.9 16.5
20.7
29.7
13.6
Adjuvant trastuzumab None 15
Luminal B breast cancer and prognostic value of HER2 overexpression: Retrospective analysis of a single-institution series.
Sub-category:
HER2+
Category:
Breast Cancer - HER2/ER
Meeting:
2011 ASCO Annual Meeting
Abstract No:
e11120
Citation:
J Clin Oncol 29: 2011 (suppl; abstr e11120)
Publication-only abstracts (abstract number preceded by an "e"), published in conjunction with the 2011 Annual Meeting but not presented at the Meeting, can be found online only.
The publication-only abstracts are not included in the print or USB versions of the ASCO Annual Meeting Proceedings Part I, but they are citable to the Journal of Clinical Oncology as a supplement (see citation on left).
Author(s): C. A. Castaneda, E. Andres, N. Valdivieso, M. Dorta, L. Manso, I. Ghanem, H. Cortes-Funes, E. M. Ciruelos Gil; Hospital Universitario 12 de Octubre, Madrid, Spain; Unidad de Investigación, Madrid, Spain; Medical Oncology Service, Hospital Universitario 12 de Octubre, Madrid, Spain
Abstract Disclosures
Abstract:
Background: Luminal B is a heterogeneous estrogen-receptor positive breast cancer subtype, with a higher proliferation rate and a poorer prognosis than luminal A. Overexpression of HER2 oncogene identifies tumors with a different clinical behavior. This study evaluates the prognostic role of HER2 expression in luminal B tumors. Methods: We retrospectively analyzed the clinicopathologic characteristics of 2005 early breast cancer pts (I-IIIB clinical stages) diagnosed between 1997 and 2007 at our institution. 47% of pts fulfill luminal B-subtype criteria: ki67≥14%, PR<10% stained cells or HER2(+) in addition to ER≥10% stained cells. HER2 was defined as positive if Herceptest 3+or gene amplification confirmed by FISH. Results: Among 772 luminal B patients who received curative surgery for invasive breast cancer from January 1997 to June 2007, 670 patients were included in this analysis, and 212 (27,4%) cases were HER2(+). Median age was 54.4 years (range: 27-87 years). Histologic subtype was as follows: ductal 562 pts (83.9 %); lobular 82 pts (12.2%) Histologic grade: I: 15.1 %, II: 44.8 % , and III: 39 %. Tumor characteristics according to HER2 status were similar, as described in table. With a median follow-up of 82 months, overall relapse rate was 23%. Median DFS or OS were not reached. At the current analysis, no differences were observed in DFS (p 0.64) or OS (p 0.53) in Kaplan-Meier estimates between HER2 positive and negative groups. Conclusions: Luminal B subtype include populations with different behaviour and prognosis. In our series patients with HER2 (+) tumors have a similar prognosis as HER2(-) subgroup for luminal B classified patients.
Tumor or patient characteristic
HER2-negative subgroup (% pts) HER2-positive subgroup (% pts)
Median age 54.7 y 53.4 y
Median Ki67 value 20 20
Tumor size
T1
T2
T3
T4 46.2
40.3
8.6
4.2 44.9
44.9
4.8
7.2
Node status
N0
N1
N2
N3 52.0
28.8
11.8
7.2 57.5
21.7
14.6
6.13
Histologic type
Ductal
Lobular 80
15 92
5.6
Adjuvant chemotherapy
None
No taxanes nor anthracyclines
Anthracyclines without taxanes
Anthracyclines and taxanes 19.7
15.1
24.3
23.9 16.5
20.7
29.7
13.6
Adjuvant trastuzumab None 15